Introduction
Tumor tissue, like all other human tissues, depends on an adequate supply of oxygen and nutrients through the vasculature. In normal tissues, the vasculature is maintained by a fine balance between pro-and antiangiogenic soluble factors. This balance is disrupted in neoplastic tissue to favor angiogenesis, the development of a vascular system required for tumor growth (Folkman, 1995) . Angiogenesis is essential for the growth, progression and metastasis of a tumor, and inhibition of angiogenesis is an emerging anticancer therapeutic approach. However, the molecular mechanisms regulating tumor angiogenesis are still not well understood, especially in the brain. A better understanding of the mechanisms that activate angiostatic factors that normally suppress unregulated vascular growth in normal tissues is needed and could be exploited for the development of novel therapeutics for cancer and other diseases of aberrant angiogenesis (Carmeliet and Jain, 2000) .
Brain angiogenesis inhibitor 1 (BAI1) is a 1584-amino-acid protein that was found in a screen for p53-regulated genes . It is primarily expressed in the human brain although low levels are also detected in other tissues Kaur et al., 2003) . Two close homologs, BAI2 and BAI3, have been identified and are more widely expressed . The central part of BAIs predicts sevenpass transmembrane proteins and BAI1 has been shown to be localized at the cellular membrane (Mori et al., 2002) . Based on protein domain analysis, they are placed in the B family of G-protein-coupled receptors (Stacey et al., 2000) . The C-terminal intracellular domain (387 amino acids long) contains a QTEV motif that mediates binding to PDZ domain-containing proteins such as membrane associated guanylate kinase MAGI3 (Wu et al., 2000) . The BAI1 N-terminal extracellular domain is unusually large (940 amino acids) and contains a number of well-defined protein modules: a 30-amino-acid secretion signal is followed by an RGD integrin binding motif (amino acids 231-233) and five thrombospondin type 1 repeats (TSRs). Thrombospondin-1 (TSP-1) contains three TSRs that are involved in cell-cell interactions and inhibition of angiogenesis (Lawler and Hynes, 1986) . The presence of TSRs within the 120 kDa extracellular domain of BAI1 suggests a potential antiangiogenic function, and recombinant peptides encoding three 50-amino-acid TSR could inhibit angiogenesis in a rat corneal model . It remains unclear whether these repeats confer antiangiogenic properties to the full-length BAI1 receptor. In summary, BAIs are currently orphan receptors with unknown biological function.
We have previously shown BAI1 to be differentially expressed between normal brain and glioblastoma, with a lack of expression in a majority of glioma cell lines and tumor samples (Kaur et al., 2003) . Similarly, pulmonary pancreatic and gastric cancers show less BAI1 expression than their normal tissue counterparts, suggesting that tumor formation selects for lack of BAI1 expression (Hatanaka et al., 2000; Lee et al., 2001; Duda et al., 2002) . This is supported by the preliminary finding that transient BAI1 expression by adenovirus gene therapy reduces pancreatic tumor growth (Duda et al., 2002) . Taken together, these findings support the hypothesis that BAI1 function may impede tumor development through an antiangiogenic mechanism.
The mechanism by which a transmembrane protein such as BAI1 could elicit an antiangiogenic response has not been previously addressed. Here we describe a conserved G-protein-coupled receptor proteolytic cleavage site (GPS) within the extracellular domain of BAI1. We demonstrate that the proteolytic cleavage of BAI1 at this site results in the release of its extracellular domain containing five TSRs. We show that this fragment can inhibit endothelial cell migration and proliferation in vitro and can inhibit angiogenesis in vivo in the mouse matrigel plug assay. We called this cleaved extracellular fragment of BAI1 Vasculostatin. Finally, exogenous expression of Vasculostatin suppressed the growth of tumor cell xenografts in a dose-dependent manner and Vasculostatin-expressing xenografts had a reduced vessel density. This is the first example of a transmembrane protein that can release a proteolytic fragment with antiangiogenic and antineoplastic properties in vivo, representing a novel mechanism for the regulation of vascular homeostasis and tumorigenesis.
Results

Domain analysis of Brain Angiogenesis Inhibitor 1
To explain how a transmembrane protein such as BAI1 could be antiangiogenic, we hypothesized that it could be proteolytically processed to release its extracellular fragment containing the five TSRs. We searched the predicted protein sequence of BAI1 using Simple Modular Architecture Research Tool (SMART) for consensus sequence of known proteolytic cleavage sites and identified a G-protein-coupled receptor proteolytic cleavage site (GPS) at the junction of the N-terminal extracellular region with the first transmembrane domain (Figure 1a ). GPS domains are approximately 50 residues long containing either two or four conserved cysteinecs and are found by sequence homology in otherwise functionally unrelated receptors including latrophilin-1 (CL1), hCD97, Flamingo-1, sea urchin sperm receptor for egg jelly (suREJ3) and Ig Hepta (Gray et al., 1996; Krasnoperov et al., 2002; Mengerink et al., 2002) . Alignment of the GPS domains in BAI1 and other GPS-containing receptors is shown in Figure 1c . The arrowhead above the sequences indicates the putative cleavage site within this domain (Krasnoperov et al., 2002) .
BAI1 is cleaved at the GPS site
To examine whether BAI1 is processed at the GPS cleavage site, we transiently expressed BAI1 in HEK293 cells, which lack endogenous BAI1. Western blot analysis using a polyclonal antibody previously raised against a peptide from the BAI1 extracellular domain (Kaur et al., 2003) revealed the full-length protein migrating at the expected 170 kDa size in the cell lysate (Figure 1d ) while the conditioned media (CM) contained a 120 kDa secreted fragment, the size of which is compatible with proteolytic processing at the GPS cleavage site (Figure 1e ). To examine the role of the GPS domain in the cleavage of BAI1, we constructed a specific point mutation converting the conserved serine at the P1 0 site to an alanine. Point mutation of this conserved serine/threonine to an alanine has been previously shown to result in abrogation of cleavage at the GPS site for other receptors (Krasnoperov et al., 2002) . Transfection of wild-type (w.t) and the S 927 -A 927 BAI1 into 293 cells yielded full-length (170 kDa) protein in the cell lysate (Figure 1f ). In contrast, the cleaved secreted 120 kDa fragment was only found in the CM of cells transfected with w.t BAI1 (Figure 1g ). These data demonstrate that an intact S927 in the GPS domain is required for the cleavage of the 120 kDa fragment. Next, we wanted to examine whether a similar cleavage would occur in human glioma cells and verify that the observed size of the secreted fragment matches the size of the predicted cleavage product. For these experiments, we used L16 cells, a tetracycline (tet-on) responsive clone derived from the LN229 human glioma cell line with no endogenous BAI1 (Kaur et al., 2003) . We engineered a doxycycline (dox)-inducible construct expressing extracellular fragment of BAI1 (BAI1-ECD) truncated at the putative GPS cleavage site (ecBmycp-TRE2) (Figure 1b) . Expression vectors for full-length BAI1 either under the regulation of a constitutive (BAI1 pcDNA) or a tet-regulated (BAI1 pTRE2) promoter were transfected into L16 cells. Analysis of the cell lysates showed that constitutive and inducible fulllength BAI1 was expressed and migrated at the expected size of about 170 kDa (Figure 2a, arrow) , while the control truncated BAI1-ECD fragment migrated at the predicted 120 kDa (Figure 2a, arrowhead) . Actin was used as a loading control for cell lysates (Figure 2a , bottom panel). Analysis of the CM of cells transfected with both constitutive and inducible full-length BAI1 revealed the presence of a secreted 120 kDa band as in HEK293 cells (Figure 2b , lanes 2 and 3). This fragment was not observed in CM from cells transfected with the empty vector (lane 1) or without tet induction (lane 4) and its size was identical to the BAI1-ECD used for size comparison (lane 5), indicating that BAI1 is cleaved, likely at the putative GPS cleavage site. The higher molecular weight bands (indicated by an asterisk) represent homo-or heterodimers of BAI1, as they were found only in the cells transfected with BAI1 and not in the empty vector-transfected cells. G-protein-coupled receptors are known to exist as stable homo-and heterodimers and do not always resolve, even in reducing conditions (Angers et al., 2002) . TSP-1 was utilized as a loading control for CM (Figure 2b , bottom panel). Analysis of whole brain lysate obtained from mouse revealed the presence of the full length as well as cleaved secreted 120 kDa fragment in the tissue lysate. An additional 150 kDa fragment was also observed implying that there may be an additional cleavage site within the mouse BAI1 (Figure 2c ).
In vitro characterization of LN229 cells stably expressing the secreted BAI1 fragment
To study the function of the secreted BAI1-ECD, we stably transfected LN229 cells with ecBmycpcDNA expressing BAI1-ECD with a myc tag (Figure 1b) . We Expression of the extracellular BAI1 fragment has an angiostatic effect in vivo and in vitro
The cleavage of BAI1 at the GPS site releases a soluble 120 kDa fragment containing five TSRs and an integrin binding RGD motif. Based on these properties, we hypothesized that its release in the extracellular environment may have an antiangiogenic function. To examine this hypothesis, we tested the angiostatic effects of BAI1-ECD fragment-expressing cells in vivo, using the mouse matrigel plug assay. Vector control or BAI1-ECD-expressing LN229 cells were injected with matrigel subcutaneously in athymic nude mice. At 14 days after injection, the plug was removed and analysed for vascular development by histology. We observed a robust vascular channel formation in the control matrigel plugs (Figure 4a ), while it was strikingly reduced in the plugs containing BAI1-ECD-expressing cells ( Figure 4b ). von Willebrandt factor (vWF) and smooth muscle actin (SMA) staining of matrigel plugs confirmed that these structures were vascular channels as they were lined with endothelial cells that stained with vWF ( Figure 4c , arrow) and perivascular smooth muscle and pericytes that stained with SMA ( Figure 4d , arrow). We quantified the average length of the vascular channels/mm 2 and found that plugs expressing BAI1-ECD had only 11% of the average vascular channel length observed in the control plugs ( Figure 4f ). As a control, we verified the expression of BAI1-ECD in both cell types (Figure 4e ). This prompted us to further examine whether the BAI1-ECD fragment could autonomously affect the migration and proliferation of endothelial cells in vitro. CM of glioma cells transfected with ecBmycpcDNA or empty vector as a control (C) were concentrated 500 fold by ultrafiltration and tested for BAI1-ECD expression by Western blot analysis ( Figure 5 , bottom panel). The effect of BAI1-ECD on the migration of human dermal microvascular endothelial cells (HDMVECs) was evaluated using a modified Boyden chamber assay with gelatin-coated polyethylene terephthalate (PET) membranes (pore size 8 mm) as described in Materials and methods. When HDMVECs were treated with BAI1-ECD, only 46% of the cells migrated compared to the empty vector CM-treated HDMVECs (Figure 5a ).
There was a greater than 50% inhibition in the migration of HDMVECs in the presence of CM derived from BAI1-ECD-expressing cells versus control cells, indicating that BAI1-ECD could inhibit bFGF-induced migration of endothelial cells (Po0.001).
Next we examined the effect of CM derived from vector control-or BAI1-ECD-transfected cells on bFGF-induced proliferation of HDMVECs after 48 h. HDMVECs treated with BAI1 fragment CM showed an inhibition of 15% in the proliferation compared to empty vector-treated cells. While this inhibition was modest, it was significant (Po0.003) and reproducible in three independent experiments (Figure 5b) . Overall, these results show that the extracellular domain fragment of BAI1 can function autonomously as an inhibitor of vascular development independently of the transmembrane and intracellular domains of BAI1; therefore, we named it Vasculostatin.
Suppression of glioma xenograft tumorigenicity by exogenous expression of Vasculostatin
To examine whether the angiostatic function of Vasculostatin could affect tumor growth in vivo, we inoculated immunocompromised athymic nude mice with 10 7 cells of either LN229 transfected with empty vector (C), with the individual Vasculostatin-expressing clones (#13, #14) or a pooled population of five Vasculostatinexpressing clones (#11, #13, #14, #15 and #25) called the Pool select (Ps). We compared the levels of expression of Vasculostatin between the different cell types by Western blot analysis in the cell lysate and CM (Figure 6a, inset) . The relative levels of expression are #13>#14>Ps. We monitored tumor growth weekly as described in Materials and methods (Figure 6a ). After 9 weeks, the animals were killed and weights of individual tumors recorded (Figure 6b ). Control cells (C) formed rapidly growing tumors, while Vasculostatin-expressing cells grew only into small tumors, the sizes of which were inversely proportional to Vasculostatin expression levels. Clones #13, #14 and Ps exhibited 121, 14 and 4 fold suppression in tumor size at termination, respectively. To further confirm the suppressive effect of Vasculostatin expression on tumor growth, we transfected L16 glioma cells with ecBmycpTre2, a doxinducible construct expressing the myc-His-tagged Vasculostatin under the control of a tet-regulated promoter. L16 cells are LN229 cells stably transfected with rtTA making them tet responsive. The relative level of expression of Vasculostatin in these cells in the presence or absence of dox is shown in Figure 6c (inset). Exposure to dox and induction of Vasculostatin did not change the in vitro proliferation rate of these cells (not shown). To compare the effect of Vasculostatin on tumorigenicity, we inoculated immunocompromised athymic nude mice with 10 7 cells of either the parent L16 glioma cells or the dox-inducible Vasculostatinexpressing clone ec2L16. Mice were divided into two groups and Vasculostatin expression was induced in one group by feeding it dox dissolved in 4% sucrose in water (n ¼ 6/group). Tumor growth was monitored weekly 
Vasculostatin expression reduces tumor vascular density
To confirm that the suppression of tumorigenicity in the mouse xenografts involved inhibition of angiogenesis, we assessed the vessel density in the harvested xenografts. Both H&E and vWF staining of the tumors derived from the vector control cells showed a high vessel density. In contrast, tumors derived from Vasculostatin-expressing cells showed a significantly reduced vessel density (Figure 7a-d) . Quantification of the vessel density showed a respective reduction of 30, 50 and 60% for clones Ps, #14 and #13 (Figure 7e) that correlated with the level of Vasculostatin expression in the cells (Figure 7e, bottom) . We further investigated in detail the differences in size and branching between the Vasculostatin-expressing and control-derived xenografts and found that xenografts from Vasculostatin-expressing cells had reduced numbers of large (24% of control, P-value o0.0005) and small vessels (63.8%, P-value o0.05) and also showed fewer branch points (37.2% of control, P-value o0.0005) compared to control.
Discussion
BAI1 is a transmembrane orphan receptor that has been called Brain Angiogenesis Inhibitor 1 because it is preferentially expressed in the brain. We have previously shown that BAI1 expression was absent in a majority of brain tumor specimens, and our current results indicate that tumors that have lost the expression of BAI1 would have a growth advantage by being able to initiate a robust angiogenic response. Reduced BAI1 expression in glioma specimens could be due to gene silencing, posttranscriptional or post-translational control, and needs further investigation (Kaur et al., 2003) . Its extracellular domain contains five repeats with putative antiangiogenic function as they are highly homologous to TSRs. TSRs are properdin type repeats initially found in TSP-1, an extracellular matrix glycoprotein, which was the first identified naturally occurring angiogenesis inhibitor (Lawler and Hynes, 1986; Good et al., 1990; Detmar, 2000; de Fraipont et al., 2001) . TSP-1 directly binds to endothelial cells and inhibits their migration and proliferation ( its antiangiogenic activity has been mapped to two of its three TSRs. TSRs are present in over 70 human proteins and some of them confer antiangiogenic properties to their parent proteins (de Fraipont et al., 2001) . Isolated peptides containing three of the five 50 amino acid TSRs of BAI1 were shown to have an antiangiogenic function in a rat corneal model Duda et al., 2002) . This interesting preliminary finding suggested putative antiangiogenic function for BAI1 but did not provide a mechanism by which it might occur. The transmembrane nature of BAI1 was difficult to reconcile with a direct paracrine antiangiogenic function on endothelial cells. Here we provide a solution to this conundrum by showing that BAI1 is proteolytically cleaved in its extracellular N-terminal domain at a conserved GPS domain, releasing a soluble fragment (Vasculostatin) that is a potent inhibitor of angiogenesis and tumor formation. Our knowledge of the mechanism of action of TSRs on endothelium comes from the study of TSP-1. Overexpression of TSP-1 or its TSRs has been shown to inhibit tumor growth and angiogenesis in a variety of malignancies (Tolsma et al., 1993; Weinstat-Saslow et al., 1994; Volpert et al., 1998; Bleuel et al., 1999; Streit et al., 1999; Tenan et al., 2000) . TSP-1 directly interacts with endothelial cells through binding of its TSRs to CD36, a cell surface receptor. This binding then activates a signaling cascade that results in increased FasL expression leading to induction of apoptosis in endothelial cells (Dawson et al., 1997; Detmar, 2000; Jimenez et al., 2000; Volpert et al., 2002b; Simantov and Silverstein, 2003) . TSP-1 also contains an RGD integrin binding motif and integrin ligation by RGD is thought to contribute to endothelial growth inhibition. Furthermore, an RFK sequence within the second TSR in TSP-1 activates TGF-b, which can inhibit endothelial cell growth (Muller et al., 1987; Detmar, 2000) . Based on the number and position of conserved cysteines, the TSRs in BAI1 belong to group A type I TSP repeats, similar to TSP-1 TSRs (Huwiler et al., 2002) . It will be interesting to test whether Vasculostatin inhibits endothelial cell migration and proliferation via CD36 binding, integrin ligation or by other novel mechanisms.
The release of Vasculostatin occurs by proteolytic cleavage at a conserved G-protein-coupled receptor proteolytic site (GPS) in BAI1. The GPS domain is found by homology in 20 otherwise functionally unrelated G-protein-coupled receptors, and proteolytic processing of this domain has been shown for a subset of these receptors (Stacey et al., 2000) . The protease that recognizes the GPS domain and cleaves at this specific site is unknown (Krasnoperov et al., 2002) . So far, BAI1 is the only protein for which proteolytic processing at the GPS domain releases an extracellular fragment with antiangiogenic properties. It is interesting to postulate that regulation of the cleavage at the GPS domain in BAI1 may add another level of control to the balance maintained between angiogenic and antiangiogenic factors.
To our knowledge, Vasculostatin is the first example of a cleavage product of a transmembrane protein functioning as a direct paracrine antiangiogenic factor for endothelial cells. It was previously shown that some proteolytic fragments of larger proteins can have angiostatic functions. These include cleavage products of extracellular matrix proteins such as endostatin, a C-terminal fragment of collagen XVIII; tumstatin, a fragment of the noncollagenase 1 (NCI) domain of the a3 chain of type IV collagen; endorepellin, a C-terminal domain of the heparan sulfate proteoglycan perlecan; and angiostatin and K1-5, both fragments of plasminogen (O'Reilly et al., 1994 (O'Reilly et al., , 1997 Cao et al., 1999; Maeshima et al., 2000; Mongiat et al., 2003) . Vasostatin, a fragment derived from calreticullin, and PEX-c, the C-terminal cleavage product of MMP-2, also have antiangiogenic functions (Brooks et al., 1998; Pike et al., 1998) . Furthermore, platelet factor 4, and prolactin are also cleaved to release antiangiogenic molecules (Ferrara et al., 1991; Gupta et al., 1995) . In contrast to Vasculostatin, none of the above proteins contain TSRs nor do these cleavage events occur at GPS sites, suggesting that BAI1 belongs to a different class of transmembrane angioregulatory molecules.
Among the 70 proteins in the human genome that contain TSRs, a limited number are known to have an antiangiogenic function. The 20 members of the ADAMTS (a disintegrin-like and metalloproteinase with thrombospondin type 1 motif) family of secreted proteins contain variable numbers of TSRs and most of them have not yet been extensively characterized. ADAMTS-1 and ADAMTS-8 regulate angiogenesis following proteolytic processing at a consensus site for Vasculostatin is antiangiogenic and antitumorigenic B Kaur et al subtilisin (Vazquez et al., 1999; Carpizo and IruelaArispe, 2000) . BAI2 and BAI3 are two close homologs of BAI1 but have a broader tissue expression suggesting that they might have homologous functions in different organs . Both BAI2 and BAI3 have four TSRs and a conserved GPS domain, indicating that these two receptors could also be proteolytically processed to release secreted fragments with an antiangiogenic potential. The cleavage of protein domains containing TSRs might be a more general mechanism of regulating angiogenesis.
Solid tumors are characterized by increased vascularization, and the use of angiogenesis inhibitors provides an exciting prospect for therapy (Folkman, 2002) . Most of the known inhibitors of angiogenesis are also inhibitors of tumor growth. We also found that Vasculostatin inhibits tumor growth in a dose-dependent manner, providing the first example of a transmembrane receptor that can release a proteolytic fragment with direct antiangiogenic as well as antineoplastic properties.
The primarily brain-specific expression of BAI1 implies a highly specialized role for Vasculostatin in the brain. One possibility is that regulators of angiostasis with brain-specific expression may have been selected for during evolution, beyond mediating control over angiongenesis they may play a role in reinforcing the integrity of the blood-brain barrier. Recently, angiogenesis regulators have also been implicated in the formation of tight junctions and decreasing paracellular permeability, both important functions for the formation of the blood-brain barrier (Lee et al., 2003) . It is interesting to speculate that BAI1 could also be required for barrier maintenance, which is essential for brain homeostasis and proper neural function.
In summary, we have demonstrated that Vasculostatin, a natural proteolytic cleavage product of the transmembrane protein BAI1, is a potent angiogenesis inhibitor and suppressor of tumor growth. This finding opens new avenues of research for defining the regulation of this cleavage in angiostasis, vascular development and cancer prevention. A better understanding of the regulation of this event and the process by which cleavage products such as Vasculostatin can modulate endothelial function will have important implications for the treatment of tumors and also other diseases characterized by aberrant angiogenesis such as psoriasis, arthritis, macular degeneration and diabetic retinopathy.
Materials and methods
Cell culture
Glioblastoma cells were grown in DMEM supplemented with 10% FCS as described (Kaur et al., 2003) . LN229 glioma cells have a wild-type PTEN, have mutant p53 (codon 98 P-K), and are deleted in p14ARFand p16 genes. U87 glioma cells are null for PTEN, have a wild-type p53 status, and are deleted in P14ARF and P16 genes (Ishii et al., 1999) . HDMVECs were obtained from the Emory Core Facility, Department of Dermatology. The cells were used between passages 4 and 6 and were maintained in complete media MCDB131 (Mediatech), supplemented with 30% human serum (Mediatech), which was supplemented with 5 mg EGF, 0.5 mg hydrocortisone and 125 mg camp per 500 ml.
Transfections and cloning
The extracellular domain of BAI1 (amino acids 1-929) was cloned into pcDNA myc His (Invitrogen) for constitutive expression (ecBmycHispcDNA) or into pTRE2 (Clontech) for its tet-regulated expression (ecBmycHispTRE2) using standard molecular biology techniques. The point mutation (TCC to GCC) within the GPS domain was created using the Stratagene site-directed mutagenesis kit, as per the manufacturer's directions. The presence of the single point mutation was verified by sequencing the plasmid. All transfections were carried out by plating 1 Â 10 5 cells/well in six-well plates 24 h prior to transfection. In all, 1 mg of the plasmid DNA and 5 ml of GenePORTER reagent (Gene Therapy System, San Diego, CA, USA) were used for each well. Vasculostatin-or empty vector (PcDNA myc His)-transfected clones were generated by selecting for neomycin-resistant clones (400 mg/ml). The individual clones were assessed for expression of Vasculostatin by Western blot analysis. The tet-regulated system was established by stably transfecting LN229 cells with rtTA expression vector. The isolated tet responsive clone L16 was then transfected with ecbmycHispTre2 and individual gentamycin-resistant clones were isolated (400 mg/ml) and tested for their ability to induce Vasculostatin in response to dox (2 mg/ ml for 24 h).
Western blot analysis
Immunoblots were performed on cell lysates (lysed in 8 M Urea, 4% SDS, in 10 mM Tris (pH 7.4) from indicated cells or tissue. Equal amounts of protein (40 mg) were resolved on a 7.5% SDS-PAGE followed by transfer to nitrocellulose membranes. BAI1 blots were probed with anti-N-terminal anti-BAI1 (1 : 1000 dilution) antibody 14399 as described (Kaur et al., 2003) , followed by goat anti-rabbit (Cat No P0448 (1 : 1000) DAKO Co., Carpinteria, CA, USA). The CM from the indicated cells was precipitated by 15% TCA precipitation for 30 min at 41C, and then resuspended in lysis buffer. Actin blots were probed with goat anti-actin (Cat No SC16-16 (1 : 500) Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) followed by swine anti-goat antibody (Cat No 605275 (1 : 1000) Roche Molecular Biochemicals, Indianapolis, IN, USA), and TSP-1 blots were probed with mouse monoclonal anti-TSP1 antibody (Cat No MS-421 (1 : 1000) NeoMarkers, Freemont, CA, USA) followed by anti-mouseIgG (Cat No 60530 (1 : 1000) Roche Molecular Biochemicals, Indianapolis, IN, USA) and visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Proliferation assays
The proliferation rate of the different Vasculostatin-transfected and empty vector clones was assessed by crystal violet assay (Hudziak et al., 1989) . Equal numbers of cells (4000) from each clone were plated in a 96-well plate. The cells were fixed with 1% glutaraldehyde, and then stained with 0.5% crystal violet. After washing, the crystals were dissolved in Sorenson's buffer (0.025 M sodium citrate, 0.025 M citric acid in 50% ethanol) and absorbance read at A 590 nm every day for eight days.
Endothelial cell assays
CM from Vasculostatin-expressing LN229 cells (clone #13) or from empty vector-transfected cells was concentrated 500 fold using Amicon ultrafiltration concentrators with Millipore membranes (Millipore, Billerica, MA, USA; pore size 10K). Migration assays were performed using 24-well modified boyden chambers (Transwell chambers Becton Dickinson Biosciences; pore size 8 mm) coated with 0.1% gelatin as previously described (Ushio-Fukai et al., 2002) . HDMVEC cell suspensions were incubated overnight in media with 0.5% serum and complete supplements to minimize any effect by serum growth factors. HDMVEC suspension was prepared in MCDB131 with 0.2% serum and 1 Â 10 6 cells and were preincubated with CM (2 ml concentrated CM/ml of cell suspension) from empty vector-or Vasculostatin-transfected cells for 30 min at 371C in a CO 2 incubator. bFGF (10 ng/ml) was added to the lower chamber as a chemoattractant and immediately 0.5 ml of the HDMVEC suspension was added to the cell insert. After 6 h of incubation, the insert was removed and unmigrated cells were scraped off using a cotton swab. The migrated cells were fixed and stained by Diff Quik (Dade Behring Inc., Newark, DE, USA) staining and counted under a light microscope. A total of 10 random fields were counted per insert and the results expressed as mean (7s.e.) number per field. To test the effect of Vasculostatin on endothelial cell proliferation, endothelial cells were plated in a six-well plate and treated with CM derived from Vasculostatin or empty vector cells in the presence or absence of bFGF (10 ng/ml). The cells were incubated at 371C for 48 h and then assessed by crystal violet assay.
Mouse matrigel and tumor assays
Female athymic nude mice (6-week-old; NCI) were injected subcutaneously into the right lower abdomen, with either 5 Â 10 6 cells of empty vector-transfected cells or Vasculostatinexpressing (clone #13) cells in 500 ml of growth factor-reduced matrigel (BD Biosciences, Discovery labware), with 50 ng/ml of VEGF and 10 ng/ml of bFGF. The mice were killed 14 days later and the matrigel plugs were harvested and fixed in 10% buffered formalin and then embedded in paraffin. The sections were stained by H&E and endothelial cells were detected using vWF immunostaining.
For mouse tumorigenicity studies, 6-week-old female athymic nude mice (athymic ncr-nude NCI) (n ¼ 6/group) were injected subcutaneously with 10 7 cells of the indicated cell lines. For the -dox responsive cells, 12 mice/group were injected with 1 Â 10 7 cells and then six mice were fed dox (2 mg/ml) dissolved in 4% sucrose in drinking water. Tumor growth was monitored by measuring weekly the length (a) and width (b) of the tumors in individual mice. Individual mice were identified by a simple tattooing procedure (van Meir, 1997) . Tumor volume was calculated (in mm 3 ) as (a Â b 2 )/2, where boa. The experiment was repeated twice with similar results. The animals were regularly monitored and killed when they showed signs of premorbidity due to the effects of tumor burden such as lateral incumbency and over 25% weight loss (according to Institutional Animal Care and Use Committee guidelines). All animal studies were approved by the Institutional Review Board (IRB).
Histological analysis and immunohistochemistry
The harvested tumors and matrigel plugs were fixed in 10% buffered formalin for 16 h followed by paraffin embedding. The paraffin-embedded sections were stained with H&E and anti-vWF, or anti-smooth muscle actin as indicated to visualize the endothelial cells lining the vessels. The total length of channels observed in the entire matrigel plugs was quantified and then divided by the total area to calculate the channel length/mm 2 of the plug. The number of vessels/mm 2 in the tumor xenograft was quantified. Quantification of large and small vessels was performed similarly where vessels with a lumen wider than 30 mm were counted as large vessels and vessels with a lumen width smaller than 30 mm were counted as small vessels. The number of vessels per view field that were branching were counted and compared to the number of vessels that were branching in the controls. Abbreviations BAI1, Brain Angiogenesis Inhibitor 1; CM, conditioned media; BAI1-ECD, extracellular domain of BAI1; GPS, Gprotein-coupled receptor proteolytic cleavage site; TSP1, thrombospondin; TSR, thrombospondin type 1 repeats; vWF, von Willebrandt factor.
